undamentalytics Newsletter
Sign in

Korsana Biosciences, Inc. balance sheet

At the end of fiscal 2025, Korsana Biosciences, Inc. had total assets of $10.0m and shareholders' equity of $9.1m. It held $3.2m in cash against $0 of debt: net cash of $3.2m.

Balance sheet

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Cash and equivalents955454138331
Receivables—0000110
Total current assets1015955158452
Total assets18611559181310107
Accounts payable31231012
Total current liabilities18171182112
Short-term debt—444————
Total debt04440000
Shareholders' equity9859481011995
Net debt (negative = net cash)−95−51−50−10−8−3−3−1
Shares outstanding———2m2m3m4m4m

Balances at each fiscal year end (quarter end in the quarterly view). Total debt is short- plus long-term borrowings, including lease debt where the company reports it within debt. Where assets do not equal liabilities plus shareholders' equity, the difference (non-controlling interests, redeemable preferred shares) is shown on its own line.

Compare with peers

Head to head: KRSA vs MCRBKRSA vs OVIDABSI vs KRSACLGN vs KRSA

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Korsana Biosciences, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Korsana Biosciences, Inc.